Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease.
| العنوان: | Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease. |
|---|---|
| المؤلفون: | Potdar AA; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Dube S; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Naito T; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Botwin G; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Haritunians T; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Li D; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Yang S; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Bilsborough J; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Denson LA; Division of Pediatric Gastroenterology, Hepatology, and nutrition, Department of Pediatrics, University of Cincinnati college of Medicine and the Cincinnati children's Hospital Medical center, Cincinnati, OH, USA., Daly M; Broad Institute of MIT and Harvard, Cambridge, Massachusetts; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Targan SR; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Fleshner P; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Braun J; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Kugathasan S; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA., Stappenbeck TS; Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA., McGovern DPB; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. |
| المصدر: | MedRxiv : the preprint server for health sciences [medRxiv] 2020 Apr 23. Date of Electronic Publication: 2020 Apr 23. |
| نوع المنشور: | Preprint |
| اللغة: | English |
| بيانات الدورية: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| مستخلص: | Angiotensin-Converting Enzyme 2 ( ACE2 ) has been identified as the host receptor for SARS-coronavirus 2 (SARS-CoV-2) which has infected millions world-wide and likely caused hundreds of thousands of deaths. Utilizing transcriptomic data from four cohorts taken from Crohn's disease (CD) and non-inflammatory bowel disease (IBD) subjects, we observed evidence of increased ACE2 mRNA in ileum with demographic features that have been associated with poor outcomes in COVID-19 including age and raised BMI. ACE2 was downregulated in CD compared to controls in independent cohorts. Within CD, ACE2 expression was reduced in inflamed ileal tissue and also remarkably, from uninvolved tissue in patients with a worse prognosis in both adult and pediatric cohorts. In active CD, small bowel ACE2 expression was restored by anti-TNF therapy particularly in anti-TNF responders. Collectively our data suggest that ACE2 downregulation is associated with inflammation and worse outcomes in CD. |
| التعليقات: | Update in: Gastroenterology. 2021 Feb;160(3):809-822.e7. doi: 10.1053/j.gastro.2020.10.041. (PMID: 33160965) |
| References: | Nature. 2017 Oct 11;550(7675):244-248. (PMID: 29022598) Lancet Gastroenterol Hepatol. 2020 Apr;5(4):335-337. (PMID: 32087098) Am J Gastroenterol. 2020 Jun;115(6):916-923. (PMID: 32301761) J Crohns Colitis. 2019 Aug 14;13(8):1055-1066. (PMID: 30877309) Cell. 2020 May 28;181(5):1016-1035.e19. (PMID: 32413319) PLoS One. 2009 Nov 24;4(11):e7984. (PMID: 19956723) Am J Respir Crit Care Med. 2018 Aug 15;198(4):422-423. (PMID: 29634285) Nat Genet. 2017 Oct;49(10):1437-1449. (PMID: 28892060) Biol Sex Differ. 2010 Nov 05;1(1):6. (PMID: 21208466) Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184) Sci Transl Med. 2019 Jun 12;11(496):. (PMID: 31189717) Lancet Respir Med. 2020 Apr;8(4):e21. (PMID: 32171062) Nature. 2012 Jul 25;487(7408):477-81. (PMID: 22837003) Cell Host Microbe. 2018 Jun 13;23(6):716-724. (PMID: 29902437) Crohns Colitis 360. 2020 Apr;2(2):otaa026. (PMID: 32377636) Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435. (PMID: 32199469) Exp Ther Med. 2019 Jul;18(1):278-288. (PMID: 31258663) Front Immunol. 2020 Apr 15;11:557. (PMID: 32351500) Front Immunol. 2019 Oct 30;10:2565. (PMID: 31736978) N Engl J Med. 2020 Nov 26;383(22):2184-2185. (PMID: 33147384) Immunity. 2005 May;22(5):633-42. (PMID: 15894280) Lancet. 2020 Feb 15;395(10223):e30-e31. (PMID: 32032529) Lancet. 2020 May 2;395(10234):1407-1409. (PMID: 32278362) Am J Pathol. 2018 May;188(5):1183-1194. (PMID: 29454749) Nat Med. 2016 Jun;22(6):598-605. (PMID: 27158904) Gastroenterology. 2018 Sep;155(3):815-828. (PMID: 29782846) Aliment Pharmacol Ther. 2012 Feb;35(4):414-28. (PMID: 22221317) Science. 2020 Sep 11;369(6509):1318-1330. (PMID: 32913098) J Clin Med. 2020 Mar 20;9(3):. (PMID: 32244852) J Clin Invest. 2014 Aug;124(8):3617-33. (PMID: 25003194) Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14. (PMID: 18490652) Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R895-R906. (PMID: 30088946) Antioxid Redox Signal. 2013 Oct 1;19(10):1121-32. (PMID: 22462736) Gastroenterology. 2017 Dec;153(6):1504-1516.e2. (PMID: 28827067) Lancet. 2017 Apr 29;389(10080):1710-1718. (PMID: 28259484) Am J Gastroenterol. 2020 May;115(5):766-773. (PMID: 32287140) Amino Acids. 2015 Apr;47(4):693-705. (PMID: 25534429) Int J Mol Sci. 2019 Mar 13;20(6):. (PMID: 30871268) Gastroenterology. 2019 Oct;157(4):1093-1108.e11. (PMID: 31325428) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859) Eur Respir J. 2020 May 7;55(5):. (PMID: 32269088) Gastroenterology. 2009 Mar;136(3):872-82. (PMID: 19185582) Cell Metab. 2014 May 6;19(5):821-35. (PMID: 24807222) N Engl J Med. 2020 Apr 23;382(17):1653-1659. (PMID: 32227760) |
| معلومات مُعتمدة: | P01 DK046763 United States DK NIDDK NIH HHS; U01 DK062413 United States DK NIDDK NIH HHS |
| تواريخ الأحداث: | Date Created: 20200609 Latest Revision: 20240922 |
| رمز التحديث: | 20240922 |
| مُعرف محوري في PubMed: | PMC7276052 |
| DOI: | 10.1101/2020.04.19.20070995 |
| PMID: | 32511625 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.1101/2020.04.19.20070995 |
|---|